Proof of the Concept to Use a Malignant B Cell Line Drug Screen Strategy for Identification and Weight of Melphalan Resistance Genes in Multiple Myeloma

Martin Bøgsted(Chr. Hansen (Denmark)), Hans Erik Johnsen(Herlev Hospital), Alexander Schmitz(Chr. Hansen (Denmark)), Uta Bertsch(Heidelberg University), Julie Støve Bødker(Chr. Hansen (Denmark)), Anders Ellern Bilgrau(Chr. Hansen (Denmark)), Christopher P. Wardell(BMW (Germany)), Gareth J. Morgan(Hywel Dda University Health Board), Karen Dybkær(Aalborg University Hospital), Malene Krag Kjeldsen(Chr. Hansen (Denmark)), Hartmut Goldschmidt(Heidelberg University)
PLoS ONE
December 20, 2013
10.1371/journal.pone.0083252
Cited by 15

Related Papers

The Global Syndemic of Obesity, Undernutrition, and Climate Change: The Lancet Commission report
|The Lancet|2019|3.1k
Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936
|Leukemia|2003|3k
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k